120 related articles for article (PubMed ID: 38692191)
1. Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
Sun M; Li S; Liu Z; Ma S; Liu X; Meng Q; Zheng Y; Chen C
Leuk Res; 2024 Jul; 142():107507. PubMed ID: 38692191
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and Safety of Flumatinib in Treatment of Patients with Chronic Myeloid Leukemia].
Zhang Q; Qi L; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1014-1018. PubMed ID: 37551470
[TBL] [Abstract][Full Text] [Related]
3. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):728-736. PubMed ID: 38049316
[No Abstract] [Full Text] [Related]
4. [Clinical Efficacy and Safety of Flumatinib in the Treatment of Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase].
Li Q; Jing L; Wu PQ; Han LY; Xing HY; Huang CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387893
[TBL] [Abstract][Full Text] [Related]
5. [The Effect and Safety of Flumatinib in Patients with Chronic Myelogenous Leukemia Failed First-and Second-line Treatment].
Liu LY; Wei JF; Jia T; Mao JP; Cai ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):370-375. PubMed ID: 38660838
[TBL] [Abstract][Full Text] [Related]
6. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
Zhang L; Meng L; Liu B; Zhang Y; Zhu H; Cui J; Sun A; Hu Y; Jin J; Jiang H; Zhang X; Li Y; Liu L; Zhang W; Liu X; Gu J; Qiao J; Ouyang G; Liu X; Luo J; Jiang M; Xie X; Li J; Zhao C; Zhang M; Yang T; Wang J
Clin Cancer Res; 2021 Jan; 27(1):70-77. PubMed ID: 32928796
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Safety of Flumatinib in Newly Diagnosed Chronic Myelogenous Leukemia.
Jiang L; Yang M
Pharmazie; 2023 Apr; 78(1):13-16. PubMed ID: 37138411
[TBL] [Abstract][Full Text] [Related]
8. [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].
Li YY; Wang CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387894
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
[TBL] [Abstract][Full Text] [Related]
10. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
11. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
[No Abstract] [Full Text] [Related]
12. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
13. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
[TBL] [Abstract][Full Text] [Related]
17. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
18. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
19. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
20. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
